Reprogramming CAR-T cell function through synthetic cytokine receptors suppresses metastatic progression of TNBC
Patient T cells modified with chimeric antigen receptors (CARs) have shown remarkable therapeutic success in previously incurable cancers. However, despite its success in hematological malignancies, CAR-T therapy has shown only modest efficacy in solid tumors. The medical field has focused on developing new molecular d...